Drug Profile
SUN N8075
Alternative Names: SUNN8075Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Asubio Pharma
- Class Aniline compounds; Anti-ischaemics; Neuroprotectants; Piperazines
- Mechanism of Action Antioxidants; Calcium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke in European Union (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke in USA (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in Japan (Parenteral, Injection)